The market is still funding companies that feel easy to underwrite.
That does not mean simple businesses. It means simple financing logic. This week’s new rounds all have that in common. Keebler Health raised $16 million around a clear data bottleneck in healthcare. Bluefish raised $43 million by attaching its story to a measurable enterprise workflow. Gizmo raised $22 million with real user scale already in hand. NanoTech raised $29.4 million to scale products tied to existing infrastructure pain points. Terremoto raised $108 million to push specific programs through clinical development. Different sectors. Same pattern. Investors are leaning toward companies where the next milestone is obvious, and the use of funds is easy to explain.
Breadth is still expensive. Investors are rewarding companies that make the next milestone easy to picture. Not just the mission. The next proof point. The next unlock. The next reason this round matters now.
If your deck still sounds too broad, the market will make you pay for it. Your story needs a sharper wedge, a more believable next step, and less language that sounds like optionality.
A lot of founders make delegation sound soft. It is not. The best operators I know treat it like financing logic: what should stay with the founder, what should move, and what unlocks the next milestone faster.
BELAY’s delegation guide is useful if you are trying to get clearer on that before the next stage.
Protect Client Trust in Volatile Markets
When markets get shaky, advisors don’t just manage portfolios. They manage a surge of client emails, questions, and last-minute meetings. BELAY’s free Financial Advisor’s Delegation Guide shows how better delegation protects responsiveness, reduces bottlenecks, and helps your firm stay client-facing when pressure and volume rise fast across the entire firm.
Keebler Health raised $16M by fixing the part of healthcare data everyone ignores
Keebler Health raised a $16 million in Series A funding led by Flare Capital Partners, with participation from Sands Capital and existing investors. The company is focused on unstructured clinical documentation, arguing that the real value in risk adjustment lies in provider notes rather than neat, coded fields, and says the new capital will fund commercial growth, team expansion, and the infrastructure needed to serve value-based care groups nationwide. See full article.
What this means for your raise: The strongest healthcare stories right now are not “AI for healthcare.” They are much narrower. Keebler’s pitch works because the bottleneck is specific, the buyer is obvious, and the value is tied to revenue capture and workflow practicality. That is the standard.
Bluefish raised $43M because enterprise AI stories still need a real operating hook
Bluefish closed a $43 million Series B co-led by Threshold Ventures and NEA, with participation from Amex Ventures, TIAA Ventures, Salesforce Ventures, Bloomberg Beta, Crane Venture Partners, Laconia, and Swift Ventures. The company says it already works with about 10% of the Fortune 500 and processes millions of AI prompts and responses per day as brands try to understand how products are represented inside tools like ChatGPT and Gemini. See full article.
What this means for your raise: “Agentic” by itself is not a financing story. Bluefish made it one by tying the product to a budget owner, a visible enterprise problem, and proof that large brands are already buying. If you are pitching an AI company, that is the move.
Gizmo raised $22M after proving engagement at real scale
Gizmo announced a $22 million Series A led by Shine Capital, with participation from Ada Ventures, Seek Investments, GSV, NFX, and others. The company says more than 13 million learners across 120-plus countries already use its AI-powered study platform, and it plans to use the capital to expand its engineering and AI team, grow in the U.S. college market, and deepen product engagement. See full article.
What this means for your raise: Traction still shortens the argument. Gizmo did not have to sell a hypothetical future. It showed scale first, then framed the round in terms of expansion and retention. Founders should notice that order. Proof first. Story second.
NanoTech Materials raised $29.4M by staying close to painful infrastructure problems
NanoTech Materials closed a $29.4 million Series A led by HPI Real Estate & Investments, with participation from Goose Capital and Milliken & Company. The company says it will use the funding to scale operations and deepen market reach for its Cool Roof Coat, Wildfire Shield, and Insulative Coat product lines, which are aimed at energy efficiency and fire resiliency across critical infrastructure. See full article.
What this means for your raise: Not every fundable story has to feel flashy. NanoTech’s story is grounded in immediate pain, concrete products, and a visible deployment path. That makes the financing easier to believe. Sometimes “boring but necessary” is exactly what gets funded.
Terremoto Biosciences raised $108M because the round is tied to named programs, not vague ambition
Terremoto Biosciences closed a $108 million Series C with new investors including RA Capital Management, Deep Track Capital, Osage University Partners, and BeOne Medicines, alongside existing backers OrbiMed, Third Rock Ventures, Novo Holdings, and Cormorant Asset Management. The company says proceeds will advance its lead AKT1-selective inhibitor programs through Phase 1 clinical development in oncology and hereditary hemorrhagic telangiectasia. See full article.
What this means for your raise: This is a good reminder that investors do not just fund promises. They fund de-risking plans. Terremoto’s round is easy to understand because the capital is tied to specific assets and specific milestones. Founders in every category can learn from that.
Would you rather lead your deck with traction proof or with your de-risking roadmap?
The same logic applies inside the company. A sharp wedge matters, but so does execution once the money lands. Teams that know where AI actually saves time tend to move faster on the milestones that matter.
HubSpot’s guide is a useful read if you want practical ways to use ChatGPT at work without turning it into a distraction.
Want to get the most out of ChatGPT?
ChatGPT is a superpower if you know how to use it correctly.
Discover how HubSpot's guide to AI can elevate both your productivity and creativity to get more things done.
Learn to automate tasks, enhance decision-making, and foster innovation with the power of AI.
Most decks explain the company. Fewer explain the financing logic.
Write one sentence that explains why this round exists now.
Most founders can describe the company. Fewer can describe the financing logic.
Try this:
We are raising [amount] to achieve [specific milestone] in [timeframe], because doing it now unlocks [clear value creation event].
Example:
We are raising $4 million to reach $2 million ARR and 15 enterprise logos in 18 months, because that gives us a repeatable expansion story instead of a pilot-heavy Series A pitch.
That sentence does a lot of work. It forces you to connect the money to a milestone. It forces you to name the unlock. It forces you to stop treating the round like a general ambition fund.
This week’s strongest rounds all did that well. Keebler tied the raise to commercial scale. Gizmo tied it to specific market and product expansion. Terremoto tied it to Phase 1 development. Bluefish tied it to enterprise rollout. NanoTech tied it to product scale and infrastructure demand. That is what investors want to buy: progress with shape.
Flare is a useful firm to watch this week because it led Keebler Health’s Series A and sits directly in the healthcare technology lane. Flare says it is one of the largest investors dedicated to healthcare technology, and Keebler’s release says the team has invested in more than 80 companies and manages nearly $1 billion in assets.
The market is still rewarding founders who make the next milestone easy to believe. If your raise story still sounds broad, tighten the wedge and make the unlock impossible to miss.
I'm Marcus Cole. I spent four years on the investor side at a $200M seed fund in New York, reviewing 800+ decks a year, sitting in partner meetings, watching founders win and lose at the table.
Then I crossed over. Raised $4.2M across two companies. One got acqui-hired after a $1.4M raise. The other raised $2.8M seed and is still running.
I've been in your seat and theirs. Capital Raise is what I wish I'd had while raising: straight talk, no waste, built for founders who are actually in it.
Disclaimer: Capital Raise is a newsletter for informational purposes only. Nothing in this newsletter constitutes investment advice, financial advice, or a solicitation to invest.
Always do your own due diligence. Consult a licensed financial advisor before making investment decisions.